Interleukin 6 blockade in spondyloarthritis

Journal of Rheumatology

Volumn 39, Issue 5, 2012, Pages 1097-1098

  Koumakis, Eugénie ^a   Feydy, Antoine ^a   Kahan, André ^a   Allanore, Yannick ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; HLA B27 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; TOCILIZUMAB;

ADULT; BACKACHE; BAS FUNCTIONAL INDEX; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CASE REPORT; CLINICAL ASSESSMENT; DENGUE; DISEASE ACTIVITY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FUNCTIONAL ASSESSMENT; FURUNCULOSIS; HERPES ZOSTER; HUMAN; INFECTION; LETTER; MORNING STIFFNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT INFECTION; RHINOSINUSITIS; SACROILIITIS; SPONDYLARTHRITIS; URINARY TRACT INFECTION; VISUAL ANALOG SCALE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTERLEUKIN-6; MALE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860767082     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110955     Document Type: Letter

References (10)

1. Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab [letter]. J Rheumatol 2011;38:1527-8.
2. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, et al. Serum cytokines (IL-6, TNF-alpha, IL-1-beta and IFN-gamma) in ankylosing spondylitis: A close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31. (Pubitemid 24324807)
3. Wendling D, Racadot E, Toussirot E, Wijdenes J. Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. Br J Rheumatol 1996;35:1330. (Pubitemid 27032963)
4. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1-beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007;26:211-5. (Pubitemid 46020247)
5. Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: Detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 2006;65:713-20. (Pubitemid 43799168)
6. Henes JC, Horger M, Guenaydin I, Kanz L, Koetter I. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis 2010;69:2217-8.
7. Wendling D, Bossert M, Prati C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine 2010;77:624-5.
8. Brulhart L, Nissen MJ, Chevallier P, Gabay C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010;77:625-6.
9. Tanaka T, Kuwahara Y, Shima Y, Hirano T, Kawai M, Ogawa M, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum 2009;61:1762-4.
10. Shima Y, Tomita T, Ishii T, Morishima A, Maeda Y, Ogata A, et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheumatol 2011;21:436-9.